Hims & Hers Insider to Sell 69,431 Shares Following Recent Stock Rally

Rhea-AI Filing Summary

A Form 144 filing from Hims & Hers Health reveals a proposed sale of 69,431 shares of common stock with an aggregate market value of $2,914,713.38. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 23, 2025.

The securities being sold were acquired through multiple compensation events:

• 37,186 shares from stock options (February 2022)
• 9,138 RSUs (June 2024)
• 23,107 RSUs (June 2025, across three grants)

The filing also discloses previous sales by Oluyemi Okupe over the past 3 months, totaling approximately 45,923 shares between April-May 2025, with total gross proceeds of about $1.98 million. These transactions demonstrate a consistent pattern of insider sales, with most individual transactions ranging from ~1,000 to ~9,200 shares.

Positive

• None.

Negative

• Insider has sold 69,431 shares worth approximately $2.91M through Goldman Sachs, following a pattern of significant sales over the past 3 months totaling over $1.9M in additional dispositions
• The insider's recent selling pattern shows consistent large dispositions across multiple dates, with three separate sales of approximately 9,193 shares each in April and May 2025

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	69431	2914713.38	215453899	06/23/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/24/2022	Acquired as compensation -- Stock Options	Issuer			37186	02/24/2022	Compensation -- Cashless exercise / same-day sale
Common	06/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			9138	06/15/2024	Compensation
Common	06/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			12920	06/15/2025	Compensation
Common	06/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			4521	06/15/2025	Compensation
Common	06/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			5666	06/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/28/2025	1391	73392.22
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/15/2025	997	28262.86
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/02/2025	9193	269473.49
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/15/2025	9193	554521.76
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/28/2025	997	52586.76
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/02/2025	1391	40446.94
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/15/2025	997	59665.86
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/15/2025	9193	262374.66
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/15/2025	1391	39443.61
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/28/2025	9193	487558.11
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/02/2025	997	28913
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/15/2025	1391	83274.02

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many HIMS shares are being sold according to the Form 144 filing from June 2025?

According to the Form 144 filing, 69,431 shares of HIMS common stock are proposed to be sold through Goldman Sachs & Co. LLC, with an aggregate market value of $2,914,713.38.

What is the source of HIMS shares being sold in this Form 144?

The shares being sold came from multiple compensation awards: 37,186 shares from stock options acquired on 02/24/2022, and various Restricted Stock Unit (RSU) grants totaling 32,245 shares acquired on different dates in 2024 and 2025.

How many HIMS shares has Oluyemi Okupe sold in the past 3 months before this Form 144?

In the three months prior to this filing, Oluyemi Okupe executed 12 separate sales transactions totaling 44,923 shares, with gross proceeds of approximately $1.98 million between April and May 2025.

What is HIMS's total shares outstanding according to the June 2025 Form 144?

According to the Form 144 filing, HIMS has 215,453,899 shares outstanding as of June 2025.

When is the proposed sale of HIMS shares expected to occur?

The Form 144 indicates an approximate date of sale of June 23, 2025, to be executed on the NYSE through Goldman Sachs & Co. LLC.